New promising medical technology data, which is detected through blood tests, has proven biological effects of the risk of suffering from some types of breast cancer to a setback, then a preventive treatment proposal, which represents a new indication of the benefits of liquid biopsy.
This technique, also called the DNA of the Tumor, is to monitor the development of cancer by a simple blood test, not through traditional biopsy, which requires taking more comprehensive samples. The blood test, especially any presence of the DNA that tumors produce in the blood, is a very important source of genetic information.
This technology is a great scientific progress made in recent years. Recent data confirms a possible major application for it: early and without surgical intervention, the relapse of some women with hormone -dependent cancers, which is the most common type of breast cancer.
In a press conference, Professor Francois Clemans Pedar of the Korean Institute said that “a new drug” is Kamesstran (from Astrazzinica) but “before everything a new concept”, the axis of a plenary session at the 61st conference of the American Association of Clinical Oncology (ASCO) in Chicago and the subject of an article published in the “New England” magazine.
Currently, women with hormone -based breast cancer are treated in the metastatic stage in general with a mixture of medications: a hormonal treatment that reduces estrogen production (anti -aromas) and a treatment that prevents cell reproduction (CDK4/6 inhibitors).
But for about 40% of these patients, an important gene for estrogen receptors (ESR1) witnesses, which leads to resistance to hormonal therapy, and the patient’s relapse in the end.
The new technique is to detect these mutations in the blood several months before it causes a new cancer development, to change hormonal therapy and integrate it with a drug that inhibits the cell cycle, and eventually reduced the risk of re -development of the cancerous tumor.
And previously a French academic experience (BADA-1) led by Professor Bidar had reached in the fall of 2022 to this conclusion, which also formed the axis of clinical trials from the third stage (Serena-6) for a new drug from the innovation of Astrazinica.
revolutionary
Of the 3,000 patients who were surveillance through blood tests every two to 3 months, 315 of them witnessed a development of a bloodshed without the development of cancer again, and they were divided into two groups: a standard group that continued treatment, and another experimental that received Kamizterran and inhibited the cell cycle.
Patients who received this new oral treatment witnessed a decrease in the risk of cancer development by 56%, which led to the delay of the first development of the disease by about 6 months on average. After 12 months, the survival rate without the disease development reached 60.7% for patients who received Kamizterran, compared to 33.4% for other patients. After 24 months, the survival rate without the disease was 29.7%, compared to 5.4%, according to a statement by a Korean institute, praising a “revolutionary approach”.
“This represents a precedent in breast cancer, and it can be expanded to what is more than this type of cancer,” said Bedar, a liquid biopsy in front of the journalists.
About 15 years ago, research on the DNA of a spreading tumor, which can be obtained through a simple blood sample thanks to the progress of molecular biology, has continued to support thousands of scientific studies and enhance hopes in future applications.
Scientists seek to open a path towards dedicated and preventive medicine more, but also less dependent on the surgical intervention of cancer patients.
In this case, Pedar says, “It is the first time that the pharmaceutical sector has noticed the possibilities of liquid biopsy to obtain the approval of the health authorities on the molecules, which indicates that other manufacturers will rush to adopt this new method of starting treatments.”
With the continued high number of hormone breast cancer cases in various parts of the world, competition is also increasing among pharmaceutical companies to invent a new generation of hormonal treatments and benefit from them.
Astrazineica, which is increasingly focused on anti -cancer drugs, has made “Kamesstrant” the first line treatment, a strategy to try to distinguish from competing companies such as Roche, Veeser, and Elay Lily, which are conducting many experiences of this treatment family.